Barinthus Biotherapeutics (BRNS) Competitors $1.04 +0.12 (+12.68%) (As of 05:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BRNS vs. ADAP, PBYI, ELUT, BDTX, TIL, MNPR, TELO, CGEN, GALT, and JATTShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Adaptimmune Therapeutics (ADAP), Puma Biotechnology (PBYI), Elutia (ELUT), Black Diamond Therapeutics (BDTX), Instil Bio (TIL), Monopar Therapeutics (MNPR), Telomir Pharmaceuticals (TELO), Compugen (CGEN), Galectin Therapeutics (GALT), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Adaptimmune Therapeutics Puma Biotechnology Elutia Black Diamond Therapeutics Instil Bio Monopar Therapeutics Telomir Pharmaceuticals Compugen Galectin Therapeutics JATT Acquisition Adaptimmune Therapeutics (NASDAQ:ADAP) and Barinthus Biotherapeutics (NASDAQ:BRNS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, community ranking, valuation, risk and institutional ownership. Do institutionals & insiders hold more shares of ADAP or BRNS? 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 8.0% of Barinthus Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ADAP or BRNS? Adaptimmune Therapeutics has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500. Comparatively, Barinthus Biotherapeutics has a beta of -0.73, indicating that its share price is 173% less volatile than the S&P 500. Does the MarketBeat Community favor ADAP or BRNS? Adaptimmune Therapeutics received 303 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31763.02% Underperform Votes18636.98% Barinthus BiotherapeuticsOutperform Votes14100.00% Underperform VotesNo Votes Does the media favor ADAP or BRNS? In the previous week, Adaptimmune Therapeutics had 1 more articles in the media than Barinthus Biotherapeutics. MarketBeat recorded 1 mentions for Adaptimmune Therapeutics and 0 mentions for Barinthus Biotherapeutics. Barinthus Biotherapeutics' average media sentiment score of 0.43 beat Adaptimmune Therapeutics' score of 0.00 indicating that Barinthus Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Adaptimmune Therapeutics Neutral Barinthus Biotherapeutics Neutral Is ADAP or BRNS more profitable? Barinthus Biotherapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -25.43%. Barinthus Biotherapeutics' return on equity of -34.26% beat Adaptimmune Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Barinthus Biotherapeutics N/A -34.26%-29.30% Which has preferable valuation and earnings, ADAP or BRNS? Barinthus Biotherapeutics has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$175.04M0.91-$113.87M-$0.22-2.82Barinthus Biotherapeutics$14.97M2.90-$73.35M-$1.49-0.72 Do analysts recommend ADAP or BRNS? Adaptimmune Therapeutics presently has a consensus price target of $2.79, suggesting a potential upside of 349.52%. Barinthus Biotherapeutics has a consensus price target of $5.83, suggesting a potential upside of 440.12%. Given Barinthus Biotherapeutics' higher possible upside, analysts plainly believe Barinthus Biotherapeutics is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Barinthus Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAdaptimmune Therapeutics and Barinthus Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks. Ad Porter & CompanyForbes rich list released… #1 to be assassinated?Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.45M$6.84B$5.13B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-0.7210.77135.2417.51Price / Sales2.90283.871,174.53134.92Price / CashN/A56.6540.4837.95Price / Book0.225.384.884.94Net Income-$73.35M$151.62M$118.56M$225.30M7 Day Performance25.58%-4.82%14.97%-1.11%1 Month Performance29.02%2.04%15.07%7.29%1 Year Performance-67.07%16.11%34.31%23.06% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics1.6507 of 5 stars$1.04+12.7%$5.83+460.9%-71.7%$41.84M$14.97M-0.70107Negative NewsGap UpHigh Trading VolumeADAPAdaptimmune Therapeutics1.5588 of 5 stars$0.59+1.2%$2.79+374.8%+33.2%$150.23M$60.28M-2.64449PBYIPuma Biotechnology4.0735 of 5 stars$3.01+4.5%$7.00+132.6%-25.5%$147.76M$243.57M6.42185Positive NewsELUTElutia2.7176 of 5 stars$4.22+1.9%$10.00+137.0%+114.3%$145.84M$24.75M-1.59180BDTXBlack Diamond Therapeutics2.0359 of 5 stars$2.54-0.8%$15.50+510.2%-7.7%$143.73MN/A-1.9290Positive NewsTILInstil Bio2.9091 of 5 stars$22.01+0.2%$145.00+558.8%+213.9%$143.64MN/A-1.9149MNPRMonopar Therapeutics1.698 of 5 stars$27.15+7.0%$27.33+0.7%+1,564.2%$143.30MN/A-12.8810TELOTelomir PharmaceuticalsN/A$4.80-7.7%N/AN/A$142.13MN/A0.001High Trading VolumeCGENCompugen2.5258 of 5 stars$1.59-1.2%$4.00+151.6%+110.5%$141.90M$59.85M80.5068GALTGalectin Therapeutics2.3434 of 5 stars$2.26+6.9%$11.00+387.7%+32.5%$141.57MN/A-3.149Options VolumeGap UpHigh Trading VolumeJATTJATT AcquisitionN/A$8.16-24.1%N/A-45.6%$140.76MN/A0.003Gap DownHigh Trading Volume Related Companies and Tools Related Companies ADAP Competitors PBYI Competitors ELUT Competitors BDTX Competitors TIL Competitors MNPR Competitors TELO Competitors CGEN Competitors GALT Competitors JATT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BRNS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts